Abstract

Substantial progress in understanding the biology of regulatory T cells and their roles in health and disease has been achieved in the past 10 years. This has led to an increasing interest in the possibility of using regulatory T cells as a biological therapy to preserve and restore tolerance to self antigens and alloantigens. Immunotherapy by the adoptive transfer of regulatory T cells may have several advantages over conventional treatments. However, several hurdles have to be overcome before such a therapy can enter clinical practice. This Review summarizes our current knowledge of regulatory T cells, illustrates the ongoing regulatory T-cell-based clinical trials, analyses the strengths and pitfalls of this new therapeutic approach, and highlights the future perspectives.

Author affiliations

1. San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Via Olgettina-58, 20132 Milan, Italy.
2. Vita-Salute San Raffaele University, 20132 Milan, Italy.
3. San Raffaele Scientific Institute, Immunology of Diabetes Unit, 20132 Milan, Italy.

Correspondence to: Maria-Grazia Roncarolo^1,2 Email: m.roncarolo@hsr.it

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.